·PIB·15 marks·250–350 words

Rare diseases impose a disproportionate burden on patients and the health system. Critically evaluate India's policy response.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. Strengths of the policy response
  2. Weaknesses and gaps
  3. Verdict and way forward

Rare diseases are mostly genetic. They are hard to diagnose and costly to treat, and few medicines exist for them [1]. A small number of patients therefore carry a very heavy burden. India's response is built on the National Policy for Rare Diseases (NPRD), 2021 [2]. It is real progress, but it does more to pay for treatment than to make treatment easier to reach.

Strengths of the policy response

  • Dedicated framework: MoHFW approved NPRD in March 2021. It aims to cut high treatment costs and to promote indigenous research through a National Consortium [2].
  • Financial protection: patients get support of up to Rs 50 lakh each for treatment at notified Centres of Excellence (CoEs) [3].
  • Indigenous therapy: India ran its first human gene therapy trial for haemophilia A at CMC Vellore [4]. The results were published in the New England Journal of Medicine [1].
  • Genomic base: GenomeIndia has sequenced 10,000 genomes across 84 populations, which helps diagnosis suited to Indian patients. ICMR is also widening coverage of rare genetic diseases [1].

Weaknesses and gaps

  • Capped grant, lifelong need: many rare diseases need medicine for life, so a fixed cap runs out while the illness continues. The grant pays part of the cost but does not lower it [3].
  • Access depends on location: support covers treatment only at CoEs [3]. Travel and long stays near the hospital are not covered, so poor and remote families lose out first.
  • Late diagnosis: diagnosis remains difficult [1]. When detection is late, money reaches patients after avoidable damage has occurred.
  • Research-to-patient gap: gene therapy is still at the trial stage and reaches few people [4]. The Consortium has not yet turned research into low-cost products.
  • Data governance: large genomic databases raise questions of consent, privacy and benefit-sharing under the Digital Personal Data Protection Act, 2023.

Verdict and way forward

Overall, India has moved from ad hoc relief to a structured, research-backed policy. However, the response still pays part of the cost rather than lowering it. The National Consortium should take indigenous one-time therapies like the CMC Vellore model from trial to CoEs. This could let the Rs 50 lakh cap pay for a cure instead of a few years of medicine. Diagnosis should be expanded beyond CoEs, and GenomeIndia data should be used for early detection. Together, these steps would bring rare-disease care in line with Article 21's right to health and SDG 3.8 (universal health coverage).

Sources

  1. 1PIB press release: Dr Jitendra Singh at THE WEEK Health Summit 2026rare disease burden (diagnosis, cost, few medicines); NEJM publication; GenomeIndia 10,000 genomes and 84 populations; ICMR rare disease coverage
  2. 2MoHFW (PIB): National Policy for Rare Diseases, 2021approval in March 2021; aim to reduce treatment cost; National Consortium for indigenous research
  3. 3MoHFW (PIB): Financial support under NPRD 2021up to Rs 50 lakh per patient for treatment at notified Centres of Excellence
  4. 4DST: National Science Day 2024 address (haemophilia A gene therapy trial)India's first human gene therapy trial for haemophilia A at CMC Vellore

More from this note